Targeting Polyamines and Inflammation for Cancer Prevention
- 25 September 2010
- book chapter
- review article
- Published by Springer Science and Business Media LLC
- Vol. 188, 49-64
- https://doi.org/10.1007/978-3-642-10858-7_4
Abstract
Increased polyamine synthesis and inflammation have long been associated with intraepithelial neoplasia, which are risk factors for cancer development in humans. Targeting polyamine metabolism (by use of polyamine synthesis inhibitors or polyamine catabolism activators) and inflammation (by use of nonsteroidal anti-inflammatory drugs) has been studied for many cancers, including colon, prostate, and skin. Genetic epidemiology results indicate that a genetic variant associated with the expression of a polyamine biosynthetic gene is associated with risk of colon and prostate cancers. A clinical trial of difluoromethylornithine (DFMO), a selective inhibitor of polyamine synthesis, showed that the 1 year treatment duration reduced prostate volume and serum prostate-specific antigen doubling time in men with a family history of prostate cancer. A second, clinical trial of DFMO in combination with sulindac, a NSAID in patients with prior colon polyps found that the 3-year treatment was associated with a 70% reduction of all, and over a 90% reduction of advanced and/or multiple metachronous colon adenomas. In this chapter, we discuss that similar combination prevention strategies of targeting polyamines and inflammation can be effective in reducing risk factors associated with the development of human cancers.Keywords
This publication has 117 references indexed in Scilit:
- Increased spermine oxidase expression in human prostate cancer and prostatic intraepithelial neoplasia tissuesThe Prostate, 2008
- Inflammation in prostate carcinogenesisNature Reviews Cancer, 2007
- A Randomized Trial of Rofecoxib for the Chemoprevention of Colorectal AdenomasGastroenterology, 2006
- Celecoxib for the Prevention of Colorectal Adenomatous PolypsNew England Journal of Medicine, 2006
- Celecoxib for the Prevention of Sporadic Colorectal AdenomasNew England Journal of Medicine, 2006
- A Randomized Trial of Aspirin to Prevent Colorectal AdenomasNew England Journal of Medicine, 2003
- A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal CancerNew England Journal of Medicine, 2003
- Inflammation and cancerNature, 2002
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- The Hallmarks of CancerCell, 2000